On February 26th, BeiGene released its 2023 A-share performance report. According to the announcement, in 2023, BeiGene's product revenue was 15.504 billion yuan, compared to 8.48 billion yuan in the same period last year. The growth in product revenue was mainly due to the growth in the company's core market product sales.
As an advanced enterprise among pharmaceutical companies listed on the Science and Technology Innovation Board, in 2023, Baekje Shenzhou will shine in multiple aspects such as globalization, commercialization, and research and development innovation with its core products. The company's independently developed Zebutinib has a total global sales revenue of 9.138 billion yuan, compared to 3.829 billion yuan in the same period last year, a year-on-year increase of 138.7%, further consolidating its leading position in the field of hematology and oncology. If measured in US dollars, Zebutinib's global sales have surpassed the milestone of one billion US dollars, officially entering the ranks of blockbuster drugs. At present, all 5 indications approved for Zebutinib in China have been included in the national medical insurance directory.
In 2023, another important product of BeiGene, Terezumab, had a total sales revenue of 3.806 billion yuan, compared to 2.859 billion yuan in the same period last year, a year-on-year increase of 33.1%. Currently, Baizean& Reg; One indication has been approved in the European Union and the United Kingdom, and 12 indications have been approved in China, of which 11 indications have been included in the national medical insurance directory.
In addition, after excluding the impact of non cash items such as share payment expenses, depreciation and amortization expenses, BeiGene's adjusted operating loss during the reporting period was 5.176 billion yuan, compared to 10.679 billion yuan in the same period last year, which narrowed year-on-year.
BeiGene is expected to launch the first human clinical trial of at least 10 new molecular entities in 2024, accelerating the next phase of research and development.